Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms

IF 2.8 3区 医学 Q2 CLINICAL NEUROLOGY
Epilepsia Open Pub Date : 2024-11-21 DOI:10.1002/epi4.13099
Rujuta Sathe, Gyaneshwar Shrestha, Aria Terango, David Tabibzadeh, Rajsekar R. Rajaraman, Hiroki Nariai, Shaun A. Hussain
{"title":"Symptomatic vigabatrin-associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms","authors":"Rujuta Sathe,&nbsp;Gyaneshwar Shrestha,&nbsp;Aria Terango,&nbsp;David Tabibzadeh,&nbsp;Rajsekar R. Rajaraman,&nbsp;Hiroki Nariai,&nbsp;Shaun A. Hussain","doi":"10.1002/epi4.13099","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Vigabatrin-associated brain abnormalities on MRI (VABAM) are observed in approximately 20% of children who receive vigabatrin for treatment of infantile epileptic spasms syndrome. Although usually reversible and asymptomatic, VABAM is occasionally symptomatic. Whereas asymptomatic VABAM appears to be dose-dependent, symptomatic VABAM is possibly associated with co-administration of vigabatrin and hormonal therapy (i.e., corticosteroids or adrenocorticotropic hormone). With retrospective study of a cohort of vigabatrin-treated children, we evaluated candidate risk factors for VABAM. Among 108 children with detailed vigabatrin exposure data, we identified VABAM in 17 children (11 symptomatic). Symptomatic VABAM was strongly associated with simultaneous exposure to hormonal therapy (<i>p</i> = 0.001). Neither symptomatic nor asymptomatic VABAM were associated with peak vigabatrin dose. Although these data support the hypothesis that symptomatic VABAM risk is higher with coadministration of vigabatrin and hormonal therapy, this study does not establish a causal link. Further study is warranted to better understand the pathogenesis of VABAM and devise strategies to mitigate risk. Clinicians should carefully weigh the potential risk of symptomatic vigabatrin toxicity against the known benefit of vigabatrin and hormonal therapy coadministration.</p>\n </section>\n \n <section>\n \n <h3> Plain Language Summary</h3>\n \n <p>Several case reports suggest that the combination of vigabatrin and hormonal therapy for treatment of infantile spasms may provoke an adverse reaction known as symptomatic vigabatrin MRI toxicity (sVABAM, which includes characteristic changes on MRI images and associated symptoms). In response to these reports, we studied a large single-center cohort of children with infantile spasms and determined that combination therapy is indeed statistically associated with sVABAM. However, we have not proven that combination therapy actually causes sVABAM. Further study is needed to clarify the nature of sVABAM and risk factors thereof.</p>\n </section>\n </div>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":"10 1","pages":"314-320"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/epi4.13099","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia Open","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/epi4.13099","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Vigabatrin-associated brain abnormalities on MRI (VABAM) are observed in approximately 20% of children who receive vigabatrin for treatment of infantile epileptic spasms syndrome. Although usually reversible and asymptomatic, VABAM is occasionally symptomatic. Whereas asymptomatic VABAM appears to be dose-dependent, symptomatic VABAM is possibly associated with co-administration of vigabatrin and hormonal therapy (i.e., corticosteroids or adrenocorticotropic hormone). With retrospective study of a cohort of vigabatrin-treated children, we evaluated candidate risk factors for VABAM. Among 108 children with detailed vigabatrin exposure data, we identified VABAM in 17 children (11 symptomatic). Symptomatic VABAM was strongly associated with simultaneous exposure to hormonal therapy (p = 0.001). Neither symptomatic nor asymptomatic VABAM were associated with peak vigabatrin dose. Although these data support the hypothesis that symptomatic VABAM risk is higher with coadministration of vigabatrin and hormonal therapy, this study does not establish a causal link. Further study is warranted to better understand the pathogenesis of VABAM and devise strategies to mitigate risk. Clinicians should carefully weigh the potential risk of symptomatic vigabatrin toxicity against the known benefit of vigabatrin and hormonal therapy coadministration.

Plain Language Summary

Several case reports suggest that the combination of vigabatrin and hormonal therapy for treatment of infantile spasms may provoke an adverse reaction known as symptomatic vigabatrin MRI toxicity (sVABAM, which includes characteristic changes on MRI images and associated symptoms). In response to these reports, we studied a large single-center cohort of children with infantile spasms and determined that combination therapy is indeed statistically associated with sVABAM. However, we have not proven that combination therapy actually causes sVABAM. Further study is needed to clarify the nature of sVABAM and risk factors thereof.

Abstract Image

婴儿痉挛症患者在同时接受激素治疗时会出现症状性的维加巴曲林相关磁共振成像毒性。
在接受维格巴特林治疗婴儿癫痫痉挛综合征的儿童中,约有 20% 可观察到磁共振成像上与维格巴特林相关的脑部异常(VABAM)。虽然 VABAM 通常是可逆和无症状的,但偶尔也会出现症状。无症状的 VABAM 似乎与剂量有关,而有症状的 VABAM 可能与同时服用维格巴曲林和激素治疗(即皮质类固醇或促肾上腺皮质激素)有关。通过对一批接受维格巴曲林治疗的儿童进行回顾性研究,我们评估了 VABAM 的候选风险因素。在 108 名有详细维格巴特林暴露数据的儿童中,我们发现了 17 名儿童(11 名有症状)的 VABAM。有症状的 VABAM 与同时接受激素治疗密切相关(p = 0.001)。无症状或无症状 VABAM 均与维格巴曲林的峰值剂量无关。尽管这些数据支持这样的假设,即同时服用维格巴曲林和接受激素治疗时,出现症状性 VABAM 的风险会更高,但本研究并未确定两者之间存在因果关系。为了更好地了解 VABAM 的发病机制并制定降低风险的策略,有必要开展进一步的研究。临床医生应仔细权衡出现维格巴曲林毒性症状的潜在风险与维格巴曲林和激素疗法联合用药的已知益处。简要说明:一些病例报告显示,联合使用维格巴曲林和激素疗法治疗婴儿痉挛症可能会引发一种不良反应,即症状性维格巴曲林磁共振成像毒性(sVABAM,包括磁共振成像图像上的特征性变化和相关症状)。针对这些报道,我们对一个大型单中心婴儿痉挛症患儿队列进行了研究,并确定联合疗法在统计学上确实与 sVABAM 有关。然而,我们并没有证明联合疗法确实会导致抽动秽语综合征。我们还需要进一步研究,以明确脑室积液的性质及其风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia Open
Epilepsia Open Medicine-Neurology (clinical)
CiteScore
4.40
自引率
6.70%
发文量
104
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信